Prospects for a Zika Virus Vaccine

Dan H. Barouch; Stephen J. Thomas; Nelson L. Michael

doi:10.1016/j.immuni.2017.02.005

Prospects for a Zika Virus Vaccine

Dan H. Barouch^*, Stephen J. Thomas, Nelson L. Michael

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

75 Scopus citations

Abstract

A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.

Original language	English
Pages (from-to)	176-182
Number of pages	7
Journal	Immunity
Volume	46
Issue number	2
DOIs	https://doi.org/10.1016/j.immuni.2017.02.005
State	Published - 21 Feb 2017
Externally published	Yes

Access to Document

10.1016/j.immuni.2017.02.005

Cite this

@article{014fd86ba8bb4f9785047fcbb3c3bbb6,

title = "Prospects for a Zika Virus Vaccine",

abstract = "A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.",

author = "Barouch, {Dan H.} and Thomas, {Stephen J.} and Michael, {Nelson L.}",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = feb,

day = "21",

doi = "10.1016/j.immuni.2017.02.005",

language = "English",

volume = "46",

pages = "176--182",

journal = "Immunity",

issn = "1074-7613",

number = "2",

}

TY - JOUR

T1 - Prospects for a Zika Virus Vaccine

AU - Barouch, Dan H.

AU - Thomas, Stephen J.

AU - Michael, Nelson L.

PY - 2017/2/21

Y1 - 2017/2/21

N2 - A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.

AB - A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.

UR - http://www.scopus.com/inward/record.url?scp=85013977459&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2017.02.005

DO - 10.1016/j.immuni.2017.02.005

M3 - Review article

C2 - 28228277

AN - SCOPUS:85013977459

SN - 1074-7613

VL - 46

SP - 176

EP - 182

JO - Immunity

JF - Immunity

IS - 2

ER -

Prospects for a Zika Virus Vaccine

Abstract

Access to Document

Fingerprint

Cite this